Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 146Breast Neoplasms 111Prostatic Neoplasms 59Neoplasms 54Multiple Myeloma 54Lung Neoplasms 49Neoplasm Metastasis 40Ovarian Neoplasms 33Colorectal Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 31Leukemia, Lymphocytic, Chronic, B-Cell 31Recurrence 26Leukemia, Myeloid, Acute 26Carcinoma, Renal Cell 25Urinary Bladder Neoplasms 23Triple Negative Breast Neoplasms 21Small Cell Lung Carcinoma 21Myasthenia Gravis 21Endometrial Neoplasms 21Carcinoma, Hepatocellular 21Lymphoma, Large B-Cell, Diffuse 20Squamous Cell Carcinoma of Head and Neck 19Melanoma 18Lymphoma, Follicular 18Nasopharyngeal Carcinoma 17Fallopian Tube Neoplasms 16Pancreatic Neoplasms 15Non-Muscle Invasive Bladder Neoplasms 15Brain Neoplasms 15Stomach Neoplasms 14

Interventions

ribociclib 1palbociclib 1exemestane 1abemaciclib 1Letrozole 1Fulvestrant 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Unilateral Breast Neoplasms × 90 days × Clear all
NCT06760637 2026-05-19

FourLight-3

Pfizer

Phase 3 Active not recruiting
1,035 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡